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Nowadays, radiotherapy has become an integral part of the treatment regimen in various malignancies for curative or palliative
purposes. Ionizing radiation interacts with biological systems to produce free radicals, which attack various cellular components.
Radioprotectors act as prophylactic agents that are administered to shield normal cells and tissues from the harmful effects
of radiation. Melatonin has been shown to be both a direct free radical scavenger and an indirect antioxidant by stimulating
antioxidant enzymes and suppressing prooxidative enzymes activity. In addition to its antioxidant property, there have also been
reports implicating antiapoptotic function for melatonin in normal cells. Furthermore, through its antitumor and radiosensitizing
properties, treatment with melatonin may prevent tumor progression. Therefore, addition of melatonin to radiation therapy could
lower the damage inflicted to the normal tissue, leading to amore efficient tumor control by use of higher doses of irradiation during
radiotherapy. Thus, it seems that, in the future, melatonin may improve the therapeutic gain in radiation oncology treatments.
1. Introduction
Radiotherapy is used for curative or palliative purpose in
various patient malignancies [1]. It is estimated that about
50–70% of clinical oncology treatments are performed with
either radiotherapy alone or a combination of radiotherapy
and chemotherapy [2, 3]. However, radio sensitivity of nor-
mal tissues surrounding the tumor limits the therapeutic
gain. The response of the normal tissues to therapeutic
radiation exposure ranges from mild discomfort to life
threatening, and the rates of such responses often depend on
the amount and distribution of the radiation dose received by
the tissue [4, 5].
Exposure of biological systems to ionizing irradiation
leads to formation of free radicals including reactive oxygen
species (ROS) as well as reactive nitrogen species (RNS) [6].
These agents impose damage to various biomacromolecules
like the DNA, lipids, and proteins present in the cell [6].
The ability of certain radioprotective agents to provide
protection against the damaging effects of ionizing radiation
was first reported in 1949 [7]. The Walter Reed Research
Institute of theUnited States Army synthesized and examined
over 4,000 compounds in an attempt to find a suitable
radioprotector in the late 1950s [8]. However, research
efforts with synthetic radioprotectors in the past have led
to little success primarily due to the various side effect
problems [9]. The most efficient radioprotective agent of
this type, which has been tested against lethal doses of
X-rays and gamma irradiation in mice, is WR-2721, also
called amifostine [8]. Although amifostine was reported as
an applicable radioprotector in clinical radiation oncology, it
was later found to cause some undesirable side effects such
as hypotension, vomiting, nausea, sneezing, hot flashes, mild
somnolence, and hypocalcaemia [10]. Results obtained from
animal experiments show that antioxidant nutrients, like
vitamin E [11] and a large number of plant productions [12],
are protective against lethality and other radiation effects but
to a lesser degree thanmost synthetic radioprotectors such as
amifostine [11]. Since 1993, when melatonin (a pineal gland
hormone) was first identified as a free radical scavenger [13],
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a large number of papers have been published confirming
the ability of this radioprotective agent to shield against
radiation-induced damage [5, 10].
In this review, from a radiobiological point of view, we
present various features that make melatonin a potent agent
in radiation oncology.
2. Melatonin: Synthesis and Distribution
Melatonin (N-acetyl-5-methoxytryptamine), which was dis-
covered byA. Lerner in 1958 [7], is an endogenous compound
synthesized by the pineal gland in the human brain. It has
been reported that melatonin participates in the regulation
of a number of physiological and pathological processes [10].
Initially, it was identified as a molecule related to neuroen-
docrine physiology, especially reproductive physiology [15].
Later on, melatonin was found to be involved in the control
of circadian rhythms of diurnal species [15]. It is estimated
that the half-life of melatonin in serum varies between 30 and
57 minutes [7]. Due to its small size and high lipophilicity,
melatonin crosses the biological membranes and reaches
all compartments of the cell [16]. Once synthesized in the
pineal gland, melatonin is quickly released into the blood-
stream [17, 18] and then into other body fluids [19], such
as bile [20], cerebrospinal fluid (CSF) [21], saliva [22, 23],
ovarian follicular fluid [24], and semen [25]. Also, it has
been reported that melatonin can easily cross the blood-
brain barrier and it is especially taken up via the choroid
plexus [26, 27]. There has also been a report indicating that
small amounts of unmetabolized melatonin are excreted in
the urine [7]. Interestingly, it has been demonstrated that
melatonin also gets produced in extrapineal organs and
tissues such as the gastrointestinal tract, retina and lens, skin,
immune and hematopoietic cells, some reproductive organs,
and endocrine glands [28]. However, while pineal melatonin
goes to the blood and CSF and can reach all tissues, retinal
melatonin is thought to act only locally (i.e., within the eye)
[5, 13, 29].
3. Antioxidative Effect of Melatonin
Asmentioned earlier,melatonin has been shown to be a direct
free radical scavenger and an indirect antioxidant via its
stimulative effects on activities of antioxidant enzymes [5, 30]
such as superoxide dismutase (SOD), glutathione peroxidase
(GSH-Px), glutathione reductase (GR), and catalase (CAT)
[15, 31–33]. Several studies have demonstrated that melatonin
appears to ameliorate irradiation-induced injury in various
organs including the spleen [34–36], liver [37–40], lung,
colon, ileum [39], lens [29, 41], spinal cord [42–44], and brain
[45] (Table 1).
It has been shown in vitro that melatonin directly scav-
enges ∙OH, H
2
O
2
, and singlet oxygen (↑O
2
∙−) and inhibits
lipid peroxidation [15]. Melatonin also increases intracellular
glutathione levels by stimulating the synthesis of the rate-
limiting enzyme, 𝛾-glutamylcysteine synthase, which inhibits
the prooxidative enzymes nitric oxide synthase and lipoxyge-
nase [15].There is also some evidence that supportsmelatonin
in stabilizing microsomal membranes and, thereby, probably
helping them resist oxidative damage [50]. Moreover, mela-
tonin has been shown to increase the efficiency of the electron
transport chain to lower electron leakage and thus a reduction
in generation of free radicals [51].
Koc and his coworkers have shown that melatonin acts
as a radical scavenger in peripheral blood cells during
whole-body irradiation in rats [46]. Results obtained from
this study showed that both leukocyte and thrombocyte
counts were significantly protected against 5Gy gamma
irradiation following a pretreatment with 5mg/kg dose of
melatonin [46]. Koc and colleagues also investigated the
antioxidant role of melatonin (at 5 and 10mg/kg) in the
liver tissue against total-body gamma irradiation-induced
oxidative damage with a single dose of 6Gy [47]. The results
demonstrated that in irradiated rats that were pretreated with
melatonin (5 or 10mg/kg) the liver tissue malondialdehyde
(MDA) levels, as an end product of lipid peroxidation,
were significantly lowered, whereas the SOD and GSH-Px
activities were significantly increased.The authors concluded
that pretreatment with melatonin may prevent irradiation-
induced liver damage [47].
After exposure to 6Gy whole-body irradiation, liver
MDA and nitric oxide (NO) levels, two indicators of free
radicals damage, were measured by Taysi et al. [37]. Gamma
irradiation caused a significant increase in liver MDA and
NO levels. Hepatic MDA and NO levels in irradiated rats
that were pretreated with melatonin (5 or 10mg/kg) were
significantly decreased [37].
El-Missiry et al. [38] showed that treatmentwith 10mg/kg
melatonin for 4 days (daily) before acute irradiation (2 and
4Gy) significantly abolished radiation-induced elevations
in MDA and protein carbonyl levels (the oxidative stress
markers) in the liver and significantly maintained hepatic
glutathione content, glutathione-S-transferase (GST), and
catalase (CAT) activities close to the control group values.
Radiation myelopathy (RM) is known as one of the most
important complications in radiotherapy, and studies have
exhibited dose- and time-dependent radiation effects [52–
55]. Shirazi et al. [43] assessed the radioprotective effects
of melatonin on biochemical, histopathological, and clinical
manifestations of RM in the rat cervical spinal cord. Admin-
istration of melatoninmarkedly reducedMDA and increased
GSH levels when compared with the control group.
Sharma and colleagues have shown that, due to its
antioxidant properties, melatonin increases the immunity in
squirrels, by protecting their hematopoietic system and lym-
phoid organs against 2.06Gy X-ray-induced cellular toxicity
[36]. In this study, total leukocyte and lymphocyte counts
(TLC and LC) in the peripheral blood and lipid peroxidation
(LPO) status, superoxide dismutase (SOD) activities, and
total antioxidant status (TAS) were measured in the spleens
of squirrels. Pretreatment with melatonin prior to the irradi-
ation significantly increased LC, TLC, SOD activity, and TAS
status compared to irradiation only groups, whereas LPO
status was decreased [36]. In another study, a radioprotective
effect of melatonin against 5Gy gamma irradiation during
the reproductively active and inactive phases (RAP and
RIP) of Indian palm squirrels was evaluated. Results showed
that melatonin treatment before irradiation significantly
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Figure 1: Effect of melatonin pretreatment (10mg/kg) on SOD
activity of serum at 4, 24, 48, and 72 hours after exposure to 2Gy
irradiation. Vertical bars represent mean + SEM, 𝑛 = 5 for each
group. Con: control;Mel: melatonin only; 2 Gy Rad: 2Gy irradiation
only; Mel + 2Gy Rad: melatonin treatment and 2Gy irradiation.
†
𝑃 < 0.05when compared with their respective control groups, and
∗
𝑃 < 0.05 when compared with their respective 2Gy Rad groups
[14].
increased the LC and increased SOD activity in the spleen of
squirrels compared with irradiation only group [35].
In our recent study, we investigated the possible radio-
protective effects of melatonin (10mg/kg) against whole-
body irradiation (2 and 8Gy) induced oxidative damage on
rats peripheral blood at different time points after exposure.
Treatment with melatonin (10mg/kg) ameliorates harmful
effects of irradiation by increasing lymphocytes count (LC)
as well as antioxidant enzymes activity and decreasing nitric
oxide (NO) levels at all time points [14]. We concluded that
10mg/kg melatonin is likely to be an adequate concentration
for significant protection against lower dose of 2Gy (Figures
1 and 2), while it does not offer significant protection against
higher dose of 8Gy. Therefore, it seems that radioprotective
effects of melatonin are dose-dependent [14]. Moreover, our
new data obtained from other studies showed that radiation
exposure decreased levels of GSH and increased levels of
MDA in the lens and liver (Figures 3 and 4) of rats, but
these values were within normal limits when melatonin was
administered [40, 41].
Overall, these findings support the antioxidant effects
of melatonin against radiation-induced oxidative stress
(Figure 7).
4. Antiapoptotic Effect of Melatonin in
Normal Cells
Various in vitro and in vivo studies have presented evidence
that radiation-induced apoptosis may be ameliorated by
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Figure 2: Effect of melatonin pretreatment (10mg/kg) on NO
levels of serum at 4, 24, 48, and 72 hours after exposure to 2Gy
irradiation. Vertical bars represent mean + SEM, 𝑛 = 5 for each
group. Con: control;Mel: melatonin only; 2 Gy Rad: 2Gy irradiation
only; Mel + 2Gy Rad: melatonin treatment and 2Gy irradiation.
†
𝑃 < 0.05when compared with their respective control groups, and
∗
𝑃 < 0.05 when compared with their respective 2Gy Rad groups
[14].
melatonin in rat neurons [56], retinal cells [57], and bone
marrow cells [58], aswell as thymocytes inmice [59]. Another
study suggested that melatonin may modulate the apoptotic
process in the small intestine of mice exposed to 2.5Gy
gamma irradiation [60].
Recently, we have shown that melatonin plays a role
in reduction of radiation-induced apoptosis in rat’s cervical
spinal cord [62]. Results obtained from this study suggest that
melatonin has protective effects against radiation-induced
apoptosis. The principal finding in this work was that mela-
tonin increased Bcl-2 gene expression versus a significant
decrease in Bax gene expression in the irradiated spinal cord
[62]. Therefore, one possible role of melatonin in prevention
of spinal cord injury is to block radiation-induced apoptosis
[62].
Sharma and colleagues have reported that melatonin,
with its antiapoptotic properties, increased the immunity in
the squirrels by protecting their lymphoid organs against
2.06Gy X-ray-induced cellular toxicity [36]. In this study,
apoptotic percentage on the basis of morphological changes
and caspase-3 activity in melatonin pretreated group were
decreased in the spleens of squirrels compared with the
irradiation only group [36]. In another study by the same
researchers, results demonstrated an inhibitory role of mela-
tonin on caspase-3 activity in splenocytes during RAP and
RIP following gamma radiation-induced caspase-mediated
apoptosis [35].These lines of evidence suggest that melatonin
might have a role in reducing apoptosis by blocking caspase-3
activity [35].
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Figure 3: The effect of melatonin on MDA levels in rats’ liver
subjected to whole body gamma irradiation. Data represent mean
± standard error on the mean (SEM), 𝑛 = 8 animals per group.
a
𝑃 < 0.05 compared to control group, and b𝑃 < 0.05 compared
to the radiated groups [40].
In a study from our laboratory, we investigated the
capability of melatonin (at 10 and 100mg/kg dosages) in the
modification of radiation-induced apoptosis and apoptosis-
associated upstream regulators expression in rat peripheral
blood lymphocytes [61]. Irradiation-only and vehicle-plus-
irradiation groups showed a marked increase in the percent-
age of apoptotic lymphocytes, while melatonin pretreatments
in a dose-dependent manner reduced it as compared with
the irradiation-only and vehicle-plus-irradiation groups in
all time points. This reduced apoptosis by melatonin was
related to the downregulation of bax, upregulation of bcl-2,
and therefore reduction of bax/bcl-2 ratio. Our results suggest
that melatonin in these doses may provide modulation of
bax and bcl-2 expression as well as bax/bcl-2 ratio to protect
rat peripheral blood lymphocytes from gamma irradiation-
induced apoptosis (Figures 5 and 6).
These studies document the role of melatonin in inhibit-
ing radiation-induced apoptosis (Figure 7). However, our
knowledge of melatonin as an antiapoptotic agent in healthy
normal cells currently remains limited and needs further
investigations.
5. Antitumor Effect of Melatonin
In addition to its antioxidant and antiapoptotic effects on
normal cells, antitumor action of melatonin, including reg-
ulation of apoptosis or possible influence on angiogenesis of
tumor (a major mechanism responsible for tumor growth
and dissemination), has also been addressed [63]. Mills and
colleagues in a systematic review of randomized controlled
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Figure 4: The effect of melatonin on GSH levels in rats’ liver
subjected to whole body gamma irradiation. Data represent mean ±
standard error on the mean (SEM), 𝑛 = 8 animals per group. a𝑃 <
0.05 compared to control group, and b𝑃 < 0.05 compared to the
radiated groups [40].
trials and meta-analysis observed a substantial reduction in
the risk of death, low adverse events (or low side effects), and
low cost of melatonin offer a great potential for melatonin in
the treating of cancer [64].
In one of the initial studies, Lissoni and coworkers
observed that, in patients with an advanced cancer of vascular
endothelial growth factor (VEGF),melatoninmay control the
tumor growth, at least in part, by acting as a natural antian-
giogenic molecule [65]. Cui and colleagues have reported
a significant antiproliferative and apoptosis-inducing effects
for melatonin in tumor cells by using western blot analyses
for p53, Bax, and Bcl-2 expression in human umbilical vein
endothelial cells [66]. All these effects were related to cell
cycle arrest, upregulation of p53 andBax, anddownregulation
of Bcl-2. The authors concluded that these results supported
the antiangiogenic effect of melatonin in tumor cells [66].
Interestingly, oral administration of melatonin decreased the
viability and volume of the tumor Ehrlich ascites carcinoma
cells (EAC) implanted in female mice, delayed the progres-
sion of the cell cycle, and reduced the DNA content of these
cells [67].The depressed cell viability indicates thatmelatonin
might be inducing apoptosis in EAC cells [67]. Moreover, the
proliferating to apoptotic cell ratio in a colon cell line, induced
by 1,2-dimethylhydrazine in mice, was significantly lowered
when the animals were treated with melatonin [67].
Another group of researchers have examined the effect
of melatonin administration on HepG2 human hepato-
carcinoma cells [68]. Melatonin treatment induced apop-
tosis along with increased caspase-3 activity and poly
(ADP-ribose) polymerase proteolysis. Proapoptotic effects of
6 BioMed Research International
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
Negative control
0.00%
Annexin V
0.22%
PI
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
0.26%
3.89%
Control
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
0.87%
65.24%
8Gy
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
0.41%
7.03%
Vehicle
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
1.70%
67.81%
Vehicle + 8Gy
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
0.08%
5.37%
10mg/kg Mel
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
1.19%
48.25%
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
0.01%
4.38%
10
0
10
1
10
2
10
3
10
4
Annexin V
10
0
10
1
10
2
10
3
10
4
PI
2.13%
40.44%
10mg/kg Mel + 8Gy 100mg/kg Mel 100mg/kg Mel + 8Gy
Figure 5: Effect of melatonin on radiation-induced apoptosis in rats peripheral blood lymphocytes. Rats were exposed to a single whole-
body gamma ray dose of 8Gy with or without melatonin (Mel) pretreatments (10 and 100mg/kg IP 1 h before irradiation). Apoptotic and
necrotic lymphocytes were analyzed by flow cytometric assay 4 h after irradiation. Representative dot plots of one set of three independent
experiments of Annexin V and PI staining. Apoptotic lymphocytes (Annexin V+ and PI−) were displayed in the lower right quadrant and
necrotic lymphocytes (Annexin V+ and PI+) were shown in the upper right quadrant [61].
melatonin were related to cytosolic cytochrome C release,
upregulation of Bax, induction of caspase-9 activity, and
increased caspase-8 activity. The reduced cell proliferation
and alterations of cell cycle were accompanied by a significant
increase in p53 and p21 expressions. The authors concluded
that, by inducing cell death and cell cycle arrest, melatonin
might be useful as an adjuvant in hepatocarcinoma therapy
[68].
Jang and colleagues have reported that as a radiosen-
sitizer, melatonin enhances radiation-induced apoptosis in
Jurkat leukemia cells, while it reduces radiation-induced
apoptosis in normal mice splenocytes [69]. The reduced
apoptosis by melatonin in normal cells was associated with
the increase of Bcl-2 expression and a reduction of Bax/Bcl-
2 ratio through a relative decrease of p53 mRNA and
protein. The authors concluded that these differential effects
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Figure 6: Real-time quantitative RT-PCR analysis of the fold change
of bax/bcl-2 ratio at various time points after irradiation (relative to
control). Values are expressed as mean ± SEM of three independent
samples each performed in triplicate. a𝑃 < 0.01 compared to the
control group, and b𝑃 < 0.01 compared to the 8Gy and vehicle +
8Gy groups [61].
on radiation-induced apoptosis by melatonin might involve
regulation of p53 expression [69]. Thus, melatonin appears
to have radioprotective effects for normal cells and it may
also act as a radiation sensitizer for tumors in animal models
[70].
According to the above lines of evidence, we propose
some possible mechanisms for various effects of melatonin
in Figure 7.
6. Melatonin and Other Radioprotectors
6.1. Melatonin and Amifostine. Among the various synthetic
radioprotectors, amifostine has a large number of clinical
applications and is currently in use as an adjuvant in
radiotherapy [71, 72]. The synthesis of amifostine [S-2-(3-
aminopropylamino) ethylphosphorothioic acid] was a major
progress in the development of radioprotective drugs [73].
However, although amifostine was used well in many clinical
trials, it remains to be expensive, and its use is limited
to clinical settings because it must be given intravenously,
and it has various undesirable side effects including nausea,
vomiting, flushes, mild somnolence, hypocalcaemia, and hy-
potension [10, 74].
A significant advantage of amifostine overmelatoninmay
be its differential and selective uptake only in normal but not
in tumor cells [75, 76]. In contrast, melatonin, as a lipophilic
molecule, can enter any cell compartment and does not seem
to produce any serious side effects [77].
As mentioned earlier, some studies indicate that mela-
tonin itself has antitumor effects [78]. Therefore, the com-
bination of these agents might also prove useful because
amifostine itself does not seem to reduce antitumor activity
of another radioprotector [74]. Moreover, melatonin may
also influence DNA repair enzymes directly and/or indirectly
stimulate intracellular signals to activate genes responsible
for enzymes involved in DNA repair [79]. In support of
this hypothesis, the data reported by Kopjar and colleagues
suggest that pretreatment with a combination of amifostine
and melatonin prevents gamma irradiation-induced DNA
damage in human peripheral blood lymphocytes in vitro
[79]. Therefore, the authors have suggested that amifostine
doses should be adjusted for optimal radioprotective effect in
healthy normal cells, in order to inflict as few side effects as
possible in cancer patients. Despite the limitations of using
amifostine, this study has produced new insights that lead
to the growing body of evidence that both amifostine and
melatonin are effective radioprotectors [79]. However, before
a combination of melatonin and amifostine can be used in
clinical treatments, further experimental and clinical studies
are needed for verification.
6.2. Melatonin and Vitamin E. Treatment with vitamin E,
whether given prior to or immediately after irradiation,
reduces radiation injury via its antioxidant effects by scaveng-
ing of free radicals [80]. Vitamin E also supports the immune
system and protects bone marrow cells from the deleterious
effects of gamma radiation by not only scavenging free
radicals but also stimulating the DNA repair machinery [81].
Vitamin E has also been reported to maintain jejunal, ileal,
and colonic fluid absorption in irradiated rats [82]. Inter-
estingly, even when administered after 1 Gy of irradiation,
vitamin E demonstrates protective effects against radiation-
induced chromosomal aberrations (CA) and micronuclei
(MN) in the mouse bone marrow [80].
Siu and colleagues compared the antioxidative capacity
for vitamin E and melatonin and found a dose-dependent
response to both, with melatonin being 7.2 times more potent
than vitamin E [57]. This finding was further supported by
works from Gitto et al., on rat liver homogenates [83], and
Erol et al., on rat brain exposed to gamma irradiation [45].
Both melatonin and vitamin E protect cells from free radical
attack by donating electrons to free radicals and neutralizing
them. It should be noted that once vitamin E donates an
electron, it becomes a radical itself, loses its antioxidant
activity, and needs vitamin C to restore its antioxidant
properties. By contrast, the antioxidant action of melatonin
involves donation of two electrons; thus it does not turn into
a free radical [34]. Hence, in contrast to other antioxidants
such as vitamin E, the reaction products of melatonin with
free radicals are themselves antioxidants [34].
Results obtained from a study by Yilmaz and colleagues
show that melatonin may protect the bones from the dam-
aging effects of radiation exposure, but there was no such
protective effects observed for vitamin E [84]. In another
study by Sharma and Haldar melatonin was found to be a
more efficient antioxidant compared with vitamin E [34].
This might be due to a higher potency for melatonin in
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Figure 7: Possible mechanism for various effects of melatonin.
scavenging various free radicals generated after irradiation, as
well as stimulating other antioxidative agents such as reduced
glutathione (GSH) [34].
7. Dose- and Time-Dependent
Treatment with Melatonin
Although the results outlined from the above studies (sum-
marized in Table 1) suggest that melatonin may be effective
for a variety of disorders, the optimal dose and mode of
melatonin administration is not clear [67]. A wide dosage
range for melatonin, from physiologic to pharmacologic
concentrations, has been tested in different animal studies.
The results of these studies indicate that both the acute and
chronic toxicity of melatonin is extremely low [7].
Pretreatmentwith 0.1mg/kg ofmelatonin, given orally for
15 consecutive days, affords potential protective effect against
radiation-induced damage in mouse cerebellum [49]. It has
been shown that melatonin, at a dose as high as 250mg/kg,
is nontoxic and that high doses of melatonin are effective
in protecting mice from lethal effects of acute whole-body
irradiation [10]. In human volunteers, oral administration
of melatonin for a wide dosage range of 1–300mg, and
even up to 1 gram per day, for 30 days [85] resulted in no
observable negative side effects [7]. In one of these studies
by Vijayalaxmi and colleagues, a single oral dose of 300mg
of melatonin was given to four healthy, nonsmoking adult
human volunteers. Peripheral blood samples were collected
5–10min prior to and 1 and 2 hours after the ingestion of
melatonin.The results obtained from this work indicated that
the irradiated lymphocytes in the blood samples collected
after melatonin ingestion exhibited a significant and time-
related decrease in the extent of primary DNA damage
(the length of DNA migration and fluorescence intensity
in comet tail) and other genetic damages compared to
similarly irradiated cells [86]. Vijayalaxmi et al. observed
that protection with 10mg/kg melatonin was significantly
greater than 5mg/kg melatonin against radiation-induced
genetic damage in blood and bone marrow in CD2-F1 mice
[87]. Melatonin, given in amounts of 0.1–10mM, led to dose-
dependent suppression of ROS produced by UV light [88].
Kim and Lee assessed the protective effects of melatonin (10
and 100𝜇g) on the ovarian follicles at 2, 8, and 14 hours
after exposure to 8.3Gy of gamma irradiation. Results of this
study suggest that radioprotective effects of melatonin related
to its concentration [89]. In another important study on
hepatocarcinoma cells, different doses (1000 and 10,000𝜇M)
of melatonin were administrated for 2, 4, 6, 8, and 10 days.
Interestingly, the growth inhibition of hepatocarcinoma cells
was both dose- and time-dependent and reached amaximum
in cells treated for 10 days with 10,000𝜇M [68]. According
to these findings, it seems that higher concentration and/or
long term of melatonin administration may produce more
protection against deleterious effects of higher irradiation
doses, which leads to a more efficient tumor control by use
of higher doses of irradiation during radiotherapy.
Melatonin concentrations in the body are typically lower
during the day and reach maximal levels at night in the
darkness [7]. Ruifrok et al. reported a diurnal variation
in apoptosis, with peak levels at 8:00 and minimal levels
between 23:00 and 02:00 hours, in the small intestine of mice
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exposed to 2.5Gy of gamma irradiation [60]. The physio-
logical concentrations of radioimmunoassayable melatonin
in the human blood are approximately 0–20 pg/mL during
the day and 40–200 pg/mL during the night [90]. Therefore,
administration of melatonin during evening in the darkness
synergistically with great endogenously levels of produced
melatonin in the body at this period may be more effective
to protect against radiation-induced oxidative stress. Thus,
in our opinion, it seems that radiation therapy with supple-
mentarymelatonin leads tomore beneficial effects during the
evening hours (in the darkness) and nighttime.
Moreover, in an aging study on rats, Reiter et al. observed
much higher 8-OH-dG(8-hydroxy-2󸀠-deoxyguanosine) as
an index of DNA damage and MDA+4-HDA levels and
increased microsomal membrane rigidity (indices of oxida-
tive damage, which are also caused by ionizing irradiation) in
a variety of organs collected from 25-month-old rats when
compared with 2-month-old controls [91]. It is suggested
that a reduction in physiological levels of melatonin may
lead to the increase in oxidative damage in the elderly [15].
Therefore, based on these observations, it seems that higher
concentrations and/or long term administration ofmelatonin
must be used for aging patients than younger ones.
Intracellular melatonin does not exit from the cell.
Instead, melatonin acts in the cell to protect it from oxida-
tive/inflammatory damage. Additionally, the potent antioxi-
dant and anti-inflammatory properties of melatonin depend
on the high levels of the indoleamine that are found intracel-
lularly. Thus, for protection against higher irradiation doses,
high doses of melatonin are needed.
Despite the lack of clinical and experimental trials,
according to these studies and our own observation, an
optimal dose ofmelatoninmay be achieved by a protocol such
as (i) a low-dose pretreatment, preferably, in the evening,
for example, one week or ten days prior to irradiation; (ii)
a high-dose administration half an hour before exposure to
irradiation or radiotherapy treatment; and (iii) a low-dose
administration in the evening until the follow-up of patient
after radiotherapy.
8. Conclusion
At the present, there is no truly ideal and safe synthetic
radioprotector available. Thus, there have been numerous
attempts directed at finding an effective radioprotective agent
that can reduce and repair radiation-induced damage in
healthy normal tissue. Although the mode and optimal dose
of melatonin is still not clear, effective radioprotective actions
show that including melatonin as an adjuvant in radiation
therapy may decrease the normal tissue damage induced
by irradiation, which leads to more tumor control by use
of higher doses of irradiation during radiotherapy. Further-
more, due to its antitumor and radiosensitizing properties,
treatment with melatonin is likely to increase damage to the
tumor. Finally, based on the discussions presented earlier,
we conclude that melatonin may be efficient in improving
the therapeutic gain in future radiation oncology treatments.
However, further experiments and clinical trials on this
subject are still necessary to fully validate it.
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